ASPIRUS RIVERVIEW HOSPITAL & CLINICS — History
CCN 520033 | 3-year financial timeline | COVID resilience: 58/100
🛡️ Public data only — no PHI permitted on this instance.
$161M
Latest Revenue (FY2022)
+3.2%
Revenue CAGR (3yr)
13.1%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $151M | $164M | $161M | -1.8% | +3.2% |
| Operating Expenses | $134M | $141M | $140M | -0.3% | +2.1% |
| Operating Margin | 11.3% | 14.4% | 13.1% | -9.0% | +7.6% |
| Net Income | $17M | $24M | $21M | -10.6% | +11.1% |
| Licensed Beds | 43 | 44 | 44 | +0.0% | +1.2% |
| Total Patient Days | 8,841 | 11,181 | 13,014 | +16.4% | +21.3% |
| Medicare Day % | 28% | 26% | 25% | -5.9% | -6.3% |
| Medicaid Day % | 7% | 3% | 5% | +38.2% | -18.9% |
COVID Impact & Recovery
Resilience Score: 58/100 — Moderate — some COVID impact but recovering
Revenue recovery from FY2020 to FY2022: +6.5% ($151M → $161M)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▲ Growing
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+3.2%
This Hospital
+7.6%
State Avg
Latest Margin
13.1%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $166M | 14.0% |
| FY2024 (proj) | $171M | 14.9% |
| FY2025 (proj) | $176M | 15.8% |